Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.3.1 (
alkaline phosphatase
)
47,916
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Myosin VI has been implicated in many cellular processes including endocytosis, secretion, membrane ruffling and cell motility. We carried out a yeast two-hybrid screen and identified
TRAF6-binding protein
(
T6BP
) and nuclear dot protein 52 (NDP52) as myosin VI binding partners. Myosin VI interaction with
T6BP
and NDP52 was confirmed in vitro and in vivo and the binding sites on each protein were accurately mapped. Immunofluorescence and electron microscopy showed that
T6BP
, NDP52 and myosin VI are present at the trans side of the Golgi complex, and on vesicles in the perinuclear region. Although the SKICH domain in
T6BP
and NDP52 does not mediate recruitment into membrane ruffles, loss of
T6BP
and NDP52 in RNAi knockdown cells results in reduced membrane ruffling activity and increased stress fibre and focal adhesion formation. Furthermore, we observed in these knockdown cells an upregulation of constitutive secretion of
alkaline phosphatase
, implying that both proteins act as negative regulators of secretory traffic at the Golgi complex.
T6BP
was also found to inhibit NF-kappaB activation, implicating it in the regulation of TRAF6-mediated cytokine signalling. Thus myosin VI-
T6BP
interactions may link membrane trafficking pathways with cell adhesion and cytokine-dependent cell signalling.
...
PMID:T6BP and NDP52 are myosin VI binding partners with potential roles in cytokine signalling and cell adhesion. 1763 94